GGrantIndex
← Leaderboards

Youngho Seo

University Of California, San Francisco

$10,977,149
Attributed
$17,908,031
Total exposure
14
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY200625
$2.5M$1.9M$1.3M$625K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,908,031 · 14

By mechanism

R01$14,496,162 · 7
S10$1,846,802 · 2
K25$780,355 · 1
R21$559,712 · 3
R43$225,000 · 1

Most similar at University Of California, San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Image

Research focus

ImageDetectionPositron-Emission TomographyLabelImaging ModalityUptakeX-Ray Computed TomographyImaging TechniquesEvaluationRadiotracerStagingAreaTomography, Emission-Computed, Single-PhotonBaseRadiationResolutionPhotonsTissuesDesignMedicalPhysicsPhysiologicalRadiopharmaceuticalsMeasurement

Grant awards (38)

Systematic Testing of a TGFβ Targeted Theranostic in Preclinical Cancer$676,567
R01 · FY2025 · CA
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy$664,448
R01 · FY2025 · CA
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy$658,891
R01 · FY2025 · HL · contact PI
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy$666,104
R01 · FY2024 · HL · contact PI
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy$631,129
R01 · FY2024 · CA
Leveraging ultra-fast Cherenkov emission in scintillator-based TOF-PET by exploiting photon wavelength classification$201,875
R21 · FY2024 · EB · contact PI
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy$694,766
R01 · FY2023 · HL · contact PI
Systematic evaluation of toxicity and therapeutic efficacy in CD46 directed radioligand therapy$664,250
R01 · FY2023 · CA
High-throughput microPET/CT at UCSF Preclinical Imaging Core$661,625
S10 · FY2023 · OD · contact PI
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy$728,416
R01 · FY2022 · HL · contact PI
Energy-independent single photon molecular imaging technology$670,337
R01 · FY2022 · EB · contact PI
Molecular Imaging of CD46$201,875
R21 · FY2021 · EB · contact PI
Energy-independent single photon molecular imaging technology$624,255
R01 · FY2020 · EB · contact PI
Dynamic cardiac SPECT$601,520
R01 · FY2020 · HL · contact PI
Energy-independent single photon molecular imaging technology$647,737
R01 · FY2019 · EB · contact PI
Dynamic cardiac SPECT$597,474
R01 · FY2019 · HL · contact PI
Energy-independent single photon molecular imaging technology$681,097
R01 · FY2018 · EB · contact PI
Dynamic cardiac SPECT$594,561
R01 · FY2018 · HL · contact PI
Preclinical Dark-Field/Phase-Contrast Scanner Using X-ray Biprisms$225,000
R43 · FY2018 · EB
Dynamic cardiac SPECT$585,874
R01 · FY2017 · HL · contact PI
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy$350,001
R01 · FY2016 · CA · contact PI
Combined dual-modality SPECT/CT for small animal imaging research at UCSF$1,185,177
S10 · FY2015 · OD · contact PI
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy$51,736
R01 · FY2015 · CA · contact PI
Energy-Independent Single Photon Molecular Imaging Technology$433,853
R01 · FY2014 · EB · contact PI
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy$409,896
R01 · FY2014 · CA · contact PI
Energy-Independent Single Photon Molecular Imaging Technology$558,080
R01 · FY2013 · EB · contact PI
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy$387,639
R01 · FY2013 · CA · contact PI
Energy-Independent Single Photon Molecular Imaging Technology$592,749
R01 · FY2012 · EB · contact PI
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy$358,902
R01 · FY2012 · CA · contact PI
Energy-Independent Single Photon Molecular Imaging Technology$589,394
R01 · FY2011 · EB · contact PI
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy$376,486
R01 · FY2011 · CA · contact PI
Prostate Cancer Management with Multimodality Imaging$137,476
K25 · FY2010 · CA · contact PI
Prostate Cancer Management with Multimodality Imaging$137,476
K25 · FY2009 · CA · contact PI
Prostate Cancer Management with Multimodality Imaging$92,975
K25 · FY2009 · CA · contact PI
Novel acquisition strategies for cardiovascular functional and molecular imaging$155,962
R21 · FY2008 · HL · contact PI
Prostate Cancer Management with Multi-Modality Imaging$137,476
K25 · FY2008 · CA · contact PI
Prostate Cancer Management with Multi-Modality Imaging$137,476
K25 · FY2007 · CA · contact PI
Prostate Cancer Management with Multimodality Imaging$137,476
K25 · FY2006 · CA · contact PI